Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,681 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depressive Disorder, Major Depressive Disorder Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

NCT04711915
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Social Determinants in Cardiovascular Health and Vascular Function

NCT05772221
View directory record Official record
Conditions
Social Determinants of Health, Major Depressive Disorder, Cardiovascular Diseases
Interventions
Screening
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 28, 2026, 12:37 AM EDT
Active, not recruiting Early Phase 1 Interventional

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

NCT03573349
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 28, 2026, 12:37 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Antidepressant Effects of Nitrous Oxide

NCT05357040
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 4 Interventional Results available

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

NCT01537068
View directory record Official record
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Interventions
Desvenlafaxine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 28, 2026, 12:37 AM EDT
Not yet recruiting Phase 1 Interventional

Ketamine Biomarker Validation

NCT07307768
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
Drug
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 28, 2026, 12:37 AM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Depression

NCT07042217
View directory record Official record
Conditions
Unipolar Depression
Interventions
transcranial direct current stimulation (tDCS) and mindfulness instruction, Sham tDCS and Mindfulness
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Woodbridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

NCT02473289
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Sirukumab 50 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
21 Years to 64 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 12:37 AM EDT
Not yet recruiting Phase 2 Interventional

Ketamine Treatment for PTSD and MDD in TBI

NCT06228391
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder, Traumatic Brain Injury
Interventions
IV ketamine, Midazolam
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Positive Feedback vs. No-Feedback Games for Behavioral Change

NCT06025838
View directory record Official record
Conditions
Major Depressive Disorder, Low Mood
Interventions
positive feedback
Behavioral
Lead sponsor
Bard College
Other
Eligibility
18 Years to 34 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Annandale-on-Hudson, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression

NCT00699218
View directory record Official record
Conditions
Mood Disorder, Bipolar Disorder, Major Depression, Depression
Interventions
Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Not applicable Interventional

Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI

NCT00947232
View directory record Official record
Conditions
Multiple Sclerosis, Spinal Cord Injury
Interventions
Motivational interviewing, Education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AZD6765, Placebo to AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 4 Interventional

Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression

NCT02141776
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial direct current stimulation (t-DCS), Sham Controlled Arm
Device · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 28, 2026, 12:37 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

NCT05523817
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intermittent Theta Burst Stimulation (iTBS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 28, 2026, 12:37 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

NCT03093025
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TS-121 10 mg, TS-121 50 mg, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

NCT00285376
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
vilazodone
Drug
Lead sponsor
Genaissance Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Alamitos, California • Newport Beach, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Sep 28, 2026, 12:37 AM EDT
Completed Not applicable Interventional

Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder

NCT00247195
View directory record Official record
Conditions
Depression
Interventions
Culturally Congruent Assessment and Treatment
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 28, 2026, 12:37 AM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Major Depression

NCT04004169
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Stimulation-ON, Stimulation-OFF, Stimulation-ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 12:37 AM EDT